Market closed
Crinetics Pharmaceuticals/$CRNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Ticker
$CRNX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
437
Website
CRNX Metrics
BasicAdvanced
$3.1B
-
-$3.69
0.58
-
Price and volume
Market cap
$3.1B
Beta
0.58
52-week high
$59.95
52-week low
$31.84
Average daily volume
916K
Financial strength
Current ratio
23.045
Quick ratio
22.829
Long term debt to equity
3.364
Total debt to equity
3.904
Management effectiveness
Return on assets (TTM)
-20.46%
Return on equity (TTM)
-32.02%
Valuation
Price to revenue (TTM)
2,624.213
Price to book
2.37
Price to tangible book (TTM)
2.37
Price to free cash flow (TTM)
-11.864
Growth
Revenue change (TTM)
-74.11%
Earnings per share change (TTM)
-0.01%
3-year revenue growth (CAGR)
-1.22%
3-year earnings per share growth (CAGR)
9.67%
What the Analysts think about CRNX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Crinetics Pharmaceuticals stock.
CRNX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CRNX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CRNX News
AllArticlesVideos
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 day ago
Crinetics Pharmaceuticals, Inc (CRNX) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Crinetics Pharmaceuticals stock?
Crinetics Pharmaceuticals (CRNX) has a market cap of $3.1B as of March 12, 2025.
What is the P/E ratio for Crinetics Pharmaceuticals stock?
The price to earnings (P/E) ratio for Crinetics Pharmaceuticals (CRNX) stock is 0 as of March 12, 2025.
Does Crinetics Pharmaceuticals stock pay dividends?
No, Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next Crinetics Pharmaceuticals dividend payment date?
Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals (CRNX) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.